A new pancreatic cancer therapy has been used to treat mice in a recent study.
The study tested out a new pancreatic cancer therapy, which was tested on mice and found to be effective in killing advanced pancreatic cancer cells. The pancreatic cancer therapy is a new development on an existing treatment, called CAR T-cell immunotherapy. CAR T-cell immunotherapy works by collecting a patient’s T-Cells, modifying them in a lab and injecting them back into the patient so that they can recognise cancer cells. While it has been successful in treating some leukaemia cases and lymphomas, it only has a limited success in treating tumours.
The facts about pancreatic cancer and its current treatment:
- Pancreatic ductal adenocarcinoma (PDAC) is the fourth most common cause of cancer-related deaths
- The five-year survival rate is less than 10%
- There are few early symptoms, so the disease is often identified in the advanced stage
- Current therapies for patients with the advanced disease are only able to extend survival by a few months
These facts highlight the urgent need for a new therapy to treat patients with advanced pancreatic cancer.
What is the new pancreatic cancer therapy?
The new pancreatic cancer therapy is a ‘switchable’ CAR T-cells which was tested to see if this was more successful in treating advanced pancreatic cancer cells. To test this, the scientists transplanted human cells from people with advanced pancreatic cancer into mice.
What were the results?
The switchable CAR T-cell therapy successfully eliminated the cancer in the mice tested. The study found that the new therapy ‘induced complete remission in difficult-to-treat, patient-derived advanced pancreatic tumour models.’ The therapy has also showed success in treating pre-clinical models of breast cancer and leukaemia.
The study results show that the therapy ‘bears the potential to safely improve the outcome of patients with advanced pancreatic cancer .’